source
- Merck’s anti‑TL1A antibody tulisokibart fails Phase 2b in systemic sclerosis lung disease but succeeds in hidradenitis suppurativaMerck reported mixed Phase 2b results for its anti‑TL1A monoclonal antibody tulisokibart, acquired in the 2023 Prometheus Biosciences purchase. In patients with systemic sclerosis‑associated inter…
- Ambient scribing startups draw attention as Abridge secures $300 million fundingLast summer, a wave of ambient scribing startups captured the health-tech spotlight. These companies employ artificial-intelligence systems that listen to doctor-patient conversations and automati…